John Stageberg, MD
Radiation Oncology · Pueblo, CONPI 1861457640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Boston Scientific at 43.0% of the total. That places this record below the midpoint for radiation oncology clinicians in CO, where the typical reported total is $456.
Across 14 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$148
- Ambu Inc.$62
- Varian Medical Systems, Inc.$48
- Progenics Pharmaceuticals, Inc.$23
- Novocure Inc.$20
- AstraZeneca$19
- plus $24 from 2 others
What the payments were for
- Food & beverage$343100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $148 |
| Ambu Inc. | 1 | $62 |
| Varian Medical Systems, Inc. | 1 | $48 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Novocure Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Accuray Incorporated | 1 | $13 |
| Myriad Genetic Laboratories, Inc. | 1 | $11 |
How this compares
$343 in reported general payments places this provider in the 40th percentile of 105 radiation oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 128 | $1,328 |
| Lidocaine Hcl ViscousLidocaine Hcl | 24 | $258 |
| Memantine Hcl | 12 | $93 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $29 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Pueblo
- Peter RossiGlenwood Springs$146K
- Suraj SinghGreely$134K
- Meera PatelAurora$112K
- David RabenAurora$61K
- Dustin BootheGreeley$55K
- Kevin ScheweThornton$51K
- Christine FisherAurora$28K
- Thomas PughDenver$15K
- Karyn GoodmanAurora$12K
- Jonathan ClarkDurango$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.